Treatment of acute leukemia and malignant lymphoma with (2?R)-4?-O-tetrahydropyranyladriamycin

Ohno, Ryuzo; Kimura, Kiyoji; Amaki, I; Hirano, Masami; Hoshino, Akira; Ikeda, Yasushi; Kimura, Ikuro; Kobayashi, Masahide; Konno, Kiyoshi; Majima, H; Masaoka, Toru; Mizuno, Harumitsu; Ogawa, Makoto; Oguro, M; Saito, Tatuo; Shimoyama, Masanori; Shirakawa, S; Sugawara, Yuzuru; Takaku, Fumimaro; Yamada, Hideo; Yamada, Kazumasa; Yamagata, Kazuya; Yoshida, Yutaka; Yoshikawa, Satoshi; Wakui, A

doi:10.1007/bf00570491

Cited by 7 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alopecia induced by ADM is also a troublesome side effect especially for female patients although it is not life-threatening. In phase II study, pirarubicin (THP) has been proved to have almost equivalent antitumor activity and similar antitumor spectrum to ADM [2] with lesser car diotoxicity and much milder alopecia [2,3], Therefore, we intended to substitute ADM by THP in VEPA [4] or CHOP [5] regimen which are common first-line chemotherapy regimens in the treatment of NHL. This is a retrospective analysis of therapeutic results obtained by the combination chemotherapy with THP, cyclophosphamide (CPM), vincristine (VCR), and prednisolone (VEP-THP therapy).…”

Section: Introductionmentioning

confidence: 99%

Combination Chemotherapy with Pirarubicin (THP), Cyclophosphamide, Vincristine, and Prednisolone (VEP-THP Therapy) in the Treatment of Non-Hodgkin’s Lymphoma

Takagi

Saito²,

Oguro³

1990

Oncology

Self Cite

View full text Add to dashboard Cite

Twenty-eight patients with non-Hodgkin’s lymphoma (NHL) were treated with a combination of (2XXX-R)-4′-o-tetrahydropyranyladriamycin (pirarubicin, THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy). Eleven (45.8%) of twenty-four evaluable patients achieved complete response (CR). CR rate (52.8%) was higher in the intermediate-grade histology group than in high- or low-grade group. Toxicity was generally acceptable although leukopenia less than 2,000/ul was observed in 17 (60.7%) of 28 patients. Clinical signs of cardiotoxicity were not observed and alopecia was mild. Therefore, VEP-THP therapy is useful as a first-line chemotherapy in the treatment of NHL, particularly for the patients with intermediate-grade histology. Higher CR rate and longer relapse-free survival can be expected by administering a greater dose of THP or employing a schedule of fractionated low doses.

show abstract

Section: Introductionmentioning

confidence: 99%

Combination Chemotherapy with Pirarubicin (THP), Cyclophosphamide, Vincristine, and Prednisolone (VEP-THP Therapy) in the Treatment of Non-Hodgkin’s Lymphoma

Takagi

Saito²,

Oguro³

1990

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

A phase i study of 4′-0-tetrahydropyranyladriamycin: Clinical pharmacology and pharmacokinetics

Sridhar

Samy

Agarwal

et al. 1990

Cancer

View full text Add to dashboard Cite

A Phase I study of intravenous (IV) bolus 4'-O-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors. Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction. A total of 167 courses at doses of 15 to 70 mg/m2 were evaluable. Maximum tolerated dose in good-risk patients was 70 mg/mz, and in poor-risk patients, 60 mg/m2. The dose-limiting toxic effect was transient noncumulative granulocytopenia. Granulocyte nadir was on day 14 (range, 4-22). Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T ' /z a (+SE) of 2.5 f 0.85 minutes, TB l/z of 25.6 rt 6.5 minutes, and T y of 23.6-t 7.6 hours. The area under the curve was 537-t 149 ng/ml X hours, volume of distribution (V,) 3504 t 644 l/mz, and total clearance ((21,) was 204 + 39.3 l/hour/mz. Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was I 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was I 10%. Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma. The recommended starting dose for Phase I1 trials is 60 mg/m2 IV bolus every 3 weeks. Cancer 66:2082-2091,1990. IRARUBICIN (4'-0-tetrahydropyranyladriamycin) is a P synthetic analog of doxorubicin (Adriamycin). ' Pi-rarubicin (THP-Adriamycin) exhibited similar or greater antitumor activity than doxorubicin in experimental tu

show abstract

Radiofrequency capacitive hyperthermia combined with irradiation of chemotherapy for patients with invasive bladder cancers

Uchibayashi

Yamamoto

Kunimi

et al. 1995

International Urology and Nephrology

View full text Add to dashboard Cite

To assess the immediate therapeutic clinical efficacy and long-term outcome, hyperthermia in combination with irradiation or chemotherapeutic agent was used in 46 patients with invasive bladder cancer. Radiohyperthermia (RH) was employed in 19 cases and chemohyperthermia (CH) in 27 cases. Complete response (CR) was obtained in 5 and partial response (PR) in 15 of the 46 cases. One-year survival rates by the Kaplan-Meier method were 65.0% in the CR/PR group and 46.2% in the no change (NC)/progressive disease (PD) group. Five-year survival rates were 43.8% and 18.3%, showing no difference in survival rate between the CR/PR group and the NC/PD group The overall median survival period for the CR/PR group without metastasis was 61.6 months compared to 32.3 months for the NC/PD group without metastasis (P < 0.05).

show abstract

Treatment of acute leukemia and malignant lymphoma with (2?R)-4?-O-tetrahydropyranyladriamycin

Cited by 7 publications

References 15 publications

Combination Chemotherapy with Pirarubicin (THP), Cyclophosphamide, Vincristine, and Prednisolone (VEP-THP Therapy) in the Treatment of Non-Hodgkin’s Lymphoma

Combination Chemotherapy with Pirarubicin (THP), Cyclophosphamide, Vincristine, and Prednisolone (VEP-THP Therapy) in the Treatment of Non-Hodgkin’s Lymphoma

A phase i study of 4′-0-tetrahydropyranyladriamycin: Clinical pharmacology and pharmacokinetics

Radiofrequency capacitive hyperthermia combined with irradiation of chemotherapy for patients with invasive bladder cancers

Contact Info

Product

Resources

About